GeneDx (NASDAQ:WGS – Get Free Report) and Danaher (NYSE:DHR – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.
Institutional and Insider Ownership
61.7% of GeneDx shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 29.6% of GeneDx shares are owned by company insiders. Comparatively, 11.1% of Danaher shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and price targets for GeneDx and Danaher, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GeneDx | 1 | 3 | 7 | 0 | 2.55 |
| Danaher | 0 | 5 | 18 | 0 | 2.78 |
Valuation & Earnings
This table compares GeneDx and Danaher”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GeneDx | $305.45 million | 15.67 | -$52.29 million | $0.09 | 1,840.11 |
| Danaher | $24.27 billion | 6.65 | $3.90 billion | $4.85 | 47.09 |
Danaher has higher revenue and earnings than GeneDx. Danaher is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares GeneDx and Danaher’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GeneDx | 0.52% | 20.22% | 11.89% |
| Danaher | 14.44% | 10.92% | 6.99% |
Risk and Volatility
GeneDx has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, Danaher has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Summary
Danaher beats GeneDx on 8 of the 14 factors compared between the two stocks.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
